RxDoctor Payments Data

Luann Wolf

Family · Fremont, OHNPI 1831266014

Payments from drug & device makers

$4,758in general payments, 2019–2025

Across 98 payments — averaging $48.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$733
  • AstraZeneca$700
  • Jazz Pharmaceuticals Inc.$322
  • SK Life Science, Inc.$263
  • Novo Nordisk$256
  • Harmony Biosciences LLC$167
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,758 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$53,546
Medicare patients
147
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol27$42,353
OzempicSemaglutide23$26,782
MounjaroTirzepatide22$25,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,036
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,663
Atorvastatin Calcium218$2,393
Omeprazole89$1,014
Levothyroxine Sodium142$915
Pantoprazole Sodium72$836
Albuterol Sulfate HfaAlbuterol Sulfate33$796
Duloxetine Hcl25$790
Metoprolol Succinate51$786
Metformin Hcl88$728
Fluticasone Propionate61$701
Lisinopril96$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$700$42,35327 claims
Novo NordiskOzempic$256$26,78223 claims
Lilly USA, LLCMounjaro$160$25,15722 claims
GSKTrelegy Ellipta$15$13,03613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Fremont

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →